Detail akcie Incyte online

Business Summary: Incyte Corporation is a biopharmaceutical company, which is focused on the discovery, development, and commercialization of therapeutics. The Company operates in two therapeutic areas. One therapeutic area is Hematology/Oncology, which is comprised of Myeloproliferative Neoplasms and Graft-Versus-Host Disease, as well as solid tumors and hematologic malignancies. Its other therapeutic area is Inflammation and Autoimmunity, which includes its Dermatology commercial franchise. Its hematology and oncology franchise are comprised of six products, which are JAKAFI (ruxolitinib), MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab), PEMAZYRE (pemigatinib), ICLUSIG (ponatinib), NIKTIMVO (axatilimab-csfr), and ZYNYZ (retifanlimab-dlwr), as well as numerous clinical development programs. The Company's pipeline also includes two first-in-class small molecule antagonist of Mas-related G protein-coupled receptor (MRGPRX2) and INCB000547, an oral MRGPRX4 antagonist.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2025, Incyte Corp revenues increased 21% to $5.14B. Net income increased from $32.6M to $1.29B. Revenues reflect JAKAFI revenues segment increase of 11% to $3.09B, OPZELURA revenues segment increase of 33% to $678.5M, United States segment increase of 20% to $4.8B, Europe segment increase of 24% to $323.7M. Net income benefited from Other Research and development decrease of 32% to $1.18B (expense).